636 related articles for article (PubMed ID: 28215704)
1. CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression.
Spencer DH; Russler-Germain DA; Ketkar S; Helton NM; Lamprecht TL; Fulton RS; Fronick CC; O'Laughlin M; Heath SE; Shinawi M; Westervelt P; Payton JE; Wartman LD; Welch JS; Wilson RK; Walter MJ; Link DC; DiPersio JF; Ley TJ
Cell; 2017 Feb; 168(5):801-816.e13. PubMed ID: 28215704
[TBL] [Abstract][Full Text] [Related]
2. Genetic and Epigenetic Perturbations by DNMT3A-R882 Mutants Impaired Apoptosis through Augmentation of PRDX2 in Myeloid Leukemia Cells.
Bera R; Chiu MC; Huang YJ; Liang DC; Lee YS; Shih LY
Neoplasia; 2018 Nov; 20(11):1106-1120. PubMed ID: 30245403
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.
Sandoval JE; Huang YH; Muise A; Goodell MA; Reich NO
J Biol Chem; 2019 Mar; 294(13):4898-4910. PubMed ID: 30705090
[TBL] [Abstract][Full Text] [Related]
4. Mutations of R882 change flanking sequence preferences of the DNA methyltransferase DNMT3A and cellular methylation patterns.
Emperle M; Adam S; Kunert S; Dukatz M; Baude A; Plass C; Rathert P; Bashtrykov P; Jeltsch A
Nucleic Acids Res; 2019 Dec; 47(21):11355-11367. PubMed ID: 31620784
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
[TBL] [Abstract][Full Text] [Related]
6. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.
Russler-Germain DA; Spencer DH; Young MA; Lamprecht TL; Miller CA; Fulton R; Meyer MR; Erdmann-Gilmore P; Townsend RR; Wilson RK; Ley TJ
Cancer Cell; 2014 Apr; 25(4):442-54. PubMed ID: 24656771
[TBL] [Abstract][Full Text] [Related]
7. Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes.
Qu Y; Lennartsson A; Gaidzik VI; Deneberg S; Karimi M; Bengtzén S; Höglund M; Bullinger L; Döhner K; Lehmann S
Epigenetics; 2014 Aug; 9(8):1108-19. PubMed ID: 24866170
[TBL] [Abstract][Full Text] [Related]
8. The DNMT3A R882H mutant displays altered flanking sequence preferences.
Emperle M; Rajavelu A; Kunert S; Arimondo PB; Reinhardt R; Jurkowska RZ; Jeltsch A
Nucleic Acids Res; 2018 Apr; 46(6):3130-3139. PubMed ID: 29518238
[TBL] [Abstract][Full Text] [Related]
9. DNMT3A R882H mutation drives daunorubicin resistance in acute myeloid leukemia via regulating NRF2/NQO1 pathway.
Chu X; Zhong L; Dan W; Wang X; Zhang Z; Liu Z; Lu Y; Shao X; Zhou Z; Chen S; Liu B
Cell Commun Signal; 2022 Oct; 20(1):168. PubMed ID: 36303144
[TBL] [Abstract][Full Text] [Related]
10. A Model System for Studying the DNMT3A Hotspot Mutation (DNMT3A
Lu R; Wang J; Ren Z; Yin J; Wang Y; Cai L; Wang GG
Cancer Res; 2019 Jul; 79(14):3583-3594. PubMed ID: 31164355
[TBL] [Abstract][Full Text] [Related]
11. Structure-guided functional suppression of AML-associated DNMT3A hotspot mutations.
Lu J; Guo Y; Yin J; Chen J; Wang Y; Wang GG; Song J
Nat Commun; 2024 Apr; 15(1):3111. PubMed ID: 38600075
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic Perturbations by Arg882-Mutated DNMT3A Potentiate Aberrant Stem Cell Gene-Expression Program and Acute Leukemia Development.
Lu R; Wang P; Parton T; Zhou Y; Chrysovergis K; Rockowitz S; Chen WY; Abdel-Wahab O; Wade PA; Zheng D; Wang GG
Cancer Cell; 2016 Jul; 30(1):92-107. PubMed ID: 27344947
[TBL] [Abstract][Full Text] [Related]
13. DNMT3A
Chen D; Christopher M; Helton NM; Ferguson I; Ley TJ; Spencer DH
Blood Cancer J; 2018 Apr; 8(4):38. PubMed ID: 29618788
[No Abstract] [Full Text] [Related]
14. DNMT3A R882 mutation is associated with elevated expression of MAFB and M4/M5 immunophenotype of acute myeloid leukemia blasts.
Yang L; Liu Y; Zhu L; Xiao M
Leuk Lymphoma; 2015; 56(10):2914-22. PubMed ID: 25721756
[TBL] [Abstract][Full Text] [Related]
15. Persistence of DNMT3A R882 mutations during remission does not adversely affect outcomes of patients with acute myeloid leukaemia.
Bhatnagar B; Eisfeld AK; Nicolet D; Mrózek K; Blachly JS; Orwick S; Lucas DM; Kohlschmidt J; Blum W; Kolitz JE; Stone RM; Bloomfield CD; Byrd JC
Br J Haematol; 2016 Oct; 175(2):226-236. PubMed ID: 27476855
[TBL] [Abstract][Full Text] [Related]
16. DNMT3A in Leukemia.
Brunetti L; Gundry MC; Goodell MA
Cold Spring Harb Perspect Med; 2017 Feb; 7(2):. PubMed ID: 28003281
[TBL] [Abstract][Full Text] [Related]
17. [Functional role of DNMT3A mutation in acute myeloid leukemia].
Koya J; Kurokawa M
Rinsho Ketsueki; 2018; 59(5):602-610. PubMed ID: 29877252
[TBL] [Abstract][Full Text] [Related]
18. Conditional knockin of Dnmt3a R878H initiates acute myeloid leukemia with mTOR pathway involvement.
Dai YJ; Wang YY; Huang JY; Xia L; Shi XD; Xu J; Lu J; Su XB; Yang Y; Zhang WN; Wang PP; Wu SF; Huang T; Mi JQ; Han ZG; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2017 May; 114(20):5237-5242. PubMed ID: 28461508
[No Abstract] [Full Text] [Related]
19. Acute myeloid leukemia with DNMT3A mutations.
Li Y; Zhu B
Leuk Lymphoma; 2014 Sep; 55(9):2002-12. PubMed ID: 24283755
[TBL] [Abstract][Full Text] [Related]
20. The acute myeloid leukemia variant DNMT3A Arg882His is a DNMT3B-like enzyme.
Norvil AB; AlAbdi L; Liu B; Tu YH; Forstoffer NE; Michie AR; Chen T; Gowher H
Nucleic Acids Res; 2020 Apr; 48(7):3761-3775. PubMed ID: 32123902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]